-
Myeloma New Vision cilta-cel, a CAR-T therapy targeting BCMA for RRMM patients (CARTITUDE-1 study)
Time of Update: 2022-01-10
The secondary endpoints of Phase Ib and Phase II trials include strict complete response rate (sCR), complete response rate (CR), and very good partial response rate (VGPR); time to remission; negative rate of minimal residual disease (MRD) ; Progression-free survival (PFS); overall survival (OS); and pharmacokinetic and pharmacodynamic markers .
-
2021 ASH deep ploughs MM, broad extension new disease, Isatuximab research progress express
Time of Update: 2022-01-10
Poster1671 Iril Interim Analysis: Efficacy and safety evaluation of ISA combined with lenalidomide and dexamethasone (Isa-Rd) in patients with poor response to lenalidomide and dexamethasone (Rd) >>>>Research Design Iril is a phase II, multicenter study in which NDMM patients were treated with lenalidomide (25mg d1-d21 28d/cycle) and dexamethasone (40mg/week, 20mg/week for patients ≥75 years old) after enrollment .
-
Doctors Wujiang, Professor Shen Zhixiang and Professor Ma Jun, wish the world's first oral XPO1 inhibitor Celiniso to be approved for marketing!
Time of Update: 2022-01-10
In the XKd (Celinisole + Carfilzomib + Dexamethasone) regimen treatment group, RRMM patients who have previously received median 4-line therapy still have a high remission rate, with an overall ORR of 78% and a median PFS It was 23.
-
To treat this leukemia, there is finally an antibody-conjugated drug
Time of Update: 2022-01-10
▎Editor of WuXi AppTec's content team recently, an antibody-conjugated drug (ADC)-Ogaituzumab for injection Bosa; English trade name BESPONSA), approved for marketing by the National Medical Products Administration (NMPA) of China, and indicated for "adult patients with relapsed or refractory precursor B-cell acute lymphoblastic leukemia (ALL) .
-
Express for the treatment of leukemia, the FDA granted the "ready-to-use" placental-derived NK cell therapy fast track qualification
Time of Update: 2022-01-10
S. FDA has granted fast-track qualification for natural killer (NK) cell therapy CYNK-001 for the treatment of acute myeloid leukemia (AML) .
"Reference: [1] Celularity Receives Fast Track Designation from US FDA for its NK Cell Therapy CYNK-001 in Development for the Treatment of AML .
-
2021 ASH big coffee talks about Professor Bai Ou's inventory of chidamine in the treatment of peripheral T-cell lymphoma
Time of Update: 2022-01-10
The team of Professor Bai Ou from Bethune First Hospital of Jilin University explored the study of Chidamide maintenance treatment of PTCL patients and was selected as a poster presentation at this year's ASH annual meeting .
-
Deqi Pharmaceuticals PD-L1/4-1BB double antibody completed the first patient administration for the treatment of non-Hodgkin’s lymphoma.
Time of Update: 2022-01-10
December 24, 2021/eMedClub PR News/--Recently, a leading innovative global biopharmaceutical company Deqi Pharmaceuticals announced the company’s bispecific antibody (PD-L1/4-1BB) candidate product ATG-101 was administered to the first patient in the Phase 1 PROBE clinical trial in Australia, mainly for the treatment of metastatic/advanced solid tumors and B-cell non-Hodgkin’s lymphoma (B-NHL) .
-
2021 ASH big coffee talks about the progress of CML, see Professor Jiang Qian's analysis
Time of Update: 2022-01-10
FFSPS help select the best treatment strategy TKI Professor Jiang Qian: For CML patients, there are multiple scoring systems can predict the survival of patients, such as Sokal, ELTS and so on .
-
[2021 ASH Express] Focus on the prognosis study of MPN patients and the whole management of MF patients
Time of Update: 2022-01-10
In the first five phases, we have combed and summarized the survival benefits of rucotinib in the treatment of myelofibrosis (MF) patients and real-world data. We also discussed the optimal treatmen
-
2021 ASH Professor Huang Huiqiang: CD19 CAR-T is better than second-line standard treatment!
Time of Update: 2022-01-10
Yimaitong: Based on the 2021 ASH conference OUTREACH study, would you please interpret the design of the study and the difference in efficacy and safety of liso-cel in the treatment of R/R LBCL patients in outpatients and inpatients?
-
2021 ASH big coffee talks about Professor Zhang Yizhu: the application of circulating tumor DNA in childhood lymphoma
Time of Update: 2022-01-10
Professor Zhang Yizhu from the Cancer Center of Sun Yat-sen University and his team explored the analysis of circulating tumor DNA (ctDNA) in children with mature B-cell non-Hodgkin lymphoma (B-NHL) and were selected for this year's ASH poster presentation .
-
KHYG-1 NK cells expressing CD38-specific chimeric antigen receptors in Myeloma New Horizons: Validation of the concept of "off-the-shelf" therapy for multiple myeloma
Time of Update: 2022-01-10
The anti-MM effect and targeted tumor suppressor activity of CD38CAR KHYG-1 cells in primary newly diagnosed patient bone marrow mononuclear cells (BMMNCs) are based on flow cytometry cytotoxicity test, even in the case of low E:T ratio, CD38A4CAR KHYG-1 cells can effectively mediate CD38-dependent lysis on primary CD38highCD138+MM cells (n = 13) .
-
Standardized Academic Journey: China Manlin College-CLL Standards More Future
Time of Update: 2022-01-10
After the chairman's speech, the 8 contestants demonstrated their cases, each of them narrated the diagnosis and treatment experience of different CLL patients, and the leaders of local working groups from all over the country provided wonderful comments and questions on the cases, and the live discussions were enthusiastic and rewarding.
-
my country's first third-generation BCR-ABL inhibitor oribatinib was launched, hitting CML resistance!
Time of Update: 2022-01-10
It is understood that oribatinib has been approved by the National Medical Products Administration (NMPA) of China on November 25 for the treatment of resistance to any tyrosine kinase inhibitor (TKI), and uses fully validated The detection method diagnoses adult patients with chronic myeloid leukemia (CML) with T315I mutation in the chronic phase (CP) or accelerated phase (AP) .
-
Explore the "gas" that headlines can treat leukemia?
Time of Update: 2022-01-10
After Tri-CAP treatment, drug-resistant CML glycolysis is inhibited (Source: PNAS Magazine) Lactic acid, a product of aerobic glycolysis, is one of the activators of the main tumor proliferation pathway PI3K/AKT/mTOR.
-
Analysis of the third-line treatment plan and clinical outcome of ASH US patients with follicular lymphoma in 2021: a real-world study
Time of Update: 2022-01-10
Currently, treatment options for patients with relapsed or refractory FL (R/R FL) include rituximab (single agent or combination chemotherapy), radioimmunotherapy, PI3K inhibitors, and hematopoietic stem cell transplantation.
2 Clinical results The median time to progression of 3L-treated patients in the overall cohort was 16.
-
2021 ASH big coffee talks about Professor Zhang Mingzhi: PD-1 inhibitors and other research progress in the treatment of NKTCL patients
Time of Update: 2022-01-10
You and your team carried out a phase II clinical trial of tislelizumab (PD-1) combined with chidamide, lenalidomide and etoposide in the treatment of refractory/relapsed extranodal NKTCL, and were shortlisted for this year's ASH conference Can you tell me the circumstances under which you decided to carry out this research?
-
CCSC: The future of blood diseases-CAR-T treatment
Time of Update: 2022-01-09
Professor Wen-Kai Weng also gave a brief introduction to the latest study on the use of CAR-T cell therapy in the second line of R/R LBCL patients.
-
Editas, founded by Feng Zhang, initiates a clinical trial of CRISPR-Cas12a gene editing to treat β-thalassemia
Time of Update: 2022-01-09
. Recently, Editas Medicine, founded by Professor Zhang Feng, one of the founders of CRISPR gene editing, announced that its IND application for the gene editing therapy EDIT-301 for the treatment of transfusion-dependent β-thalassemia has been approved by the FDA and will be launched in 20221 The Phase 2 clinical trial aims to evaluate the safety, tolerability and preliminary efficacy of EDIT-301 in the treatment of transfusion-dependent β-thalassemia .
-
Professor Huang Haiwen from the First Affiliated Hospital of Soochow University: A case report of the application of R2-CHOP regimen to effectively treat rare four-strike polymorphic mantle cell lymphoma
Time of Update: 2022-01-09
Figure 2 Morphology and immunophenotype of quadruple-strike pleomorphic MCL: Lymphoma cells have pleomorphic morphology (A) and express CD20 (B), BCL2 (C), BCL6 (D), Cyclin D1 (E) , MYC (F), CD21 (G), P53 (H), and have a high Ki67 index (I) In view of the overexpression of BCL6, MYC, Cyclin D1 and BCL2, interphase fluorescence in situ hybridization of these related genes ( FISH) analysis .
